Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval
Authors:
Top Cited Papers
- 1 October 2025
- journal article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 182 (10) , 913-921
Abstract
The objective of this study was to comprehensively examine the real-world safety of esketamine using 58 months of postapproval data in the United States. U.S. safety data from patient monitoring forms submitted to the esketamine Risk Evaluation and Mitigation Strategy (REMS) program and reports submitted to the Janssen U.S. Global Medical Safety (US-GMS) database were evaluated (March 5, 2019, to January 5, 2024). Patient characteristics, use and dosage patterns, adverse events of interest (actively solicited reports of sedation, dissociation, and increased blood pressure), and serious adverse events following esketamine administration were described. The incidence of suicidality and drug abuse/misuse was also evaluated. Most patients were 26-55 years of age (64.3%) and female (61.1%). A total of 1,486,213 outpatient treatment sessions were completed by 58,483 patients who had at least one esketamine treatment session. Sedation, dissociation, and increased blood pressure were reported in 34.7%, 41.0%, and 0.9% of sessions, respectively. Serious adverse events were reported in <0.1% and 0.18% of treatment sessions in REMS and US-GMS, respectively; suicide rates were lower than background rates; and 210 incidences of all-cause abuse/misuse were reported. Analysis of almost 5 years of real-world use of esketamine in the United States remains consistent with the established safety profile from clinical studies and current product labeling. No new safety signals were identified.Keywords
This publication has 16 references indexed in Scilit:
- Suicide‐specific mortality among patients with treatment‐resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder aloneBrain and Behavior, 2023
- Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 studyNeuropsychopharmacology, 2023
- Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide StudyJAMA Psychiatry, 2023
- Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic reviewJournal of Psychiatric Research, 2021
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant DepressionJAMA Psychiatry, 2019
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled StudyAmerican Journal of Psychiatry, 2019
- A Word to the Wise About Intranasal EsketamineAmerican Journal of Psychiatry, 2019
- The burden of treatment-resistant depression: A systematic review of the economic and quality of life literatureJournal of Affective Disorders, 2019
- Mortality in treatment-resistant unipolar depression: A register-based cohort study in SwedenJournal of Affective Disorders, 2018
- Treatment-resistant depression and suicidalityJournal of Affective Disorders, 2018